Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

e Webcast will be available until midnight April 30, 2008.

Upcoming Events

Genzyme will host a conference call on July 23, 2008 at 11:00 a.m. Eastern to discuss financial results for the second quarter of 2008. To participate in the call, please dial 773-799-3828 and refer to pass code "Genzyme." A replay of this call will be available by dialing 402-998-1342. This call will also be Webcast live on the investor events section of http://www.genzyme.com. Replays of the call and the Webcast will be available until midnight on July 30, 2008.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Contact:

Bo Piela Patrick Flanigan

(617) 768-6579 (617) 768-6563

GENZYME CORPORATION (GENZ)

Consolidated Statements of Operations

(Unaudited, amounts in thousands, Three Months Ended

except per share amounts) March 31,

2008 2007

Total revenues $1,100,061 $883,183

Operating costs and expenses:

Cost of products and services sold (1) 272,313 202,463

Selling, general and administrative (1) 318,386 269,021

Research and development (1,2) 262,797 166,120

Amortization of intangibles 55,658 50,017

Total operating costs and expenses 909,154 687,621

Operating income (loss) 190,907 195,562

Other income (expenses):

Equity in income of equi
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... One of the major revolutions taking place in healthcare ... practice of using genomic and other molecular analyses to ... diagnostics—laboratory analyses that inform the practice of personalized medicine—will ... fall, AACC ,s first ever virtual conference ... field and the novel technologies driving it forward, all ...
(Date:8/1/2014)... August 1, 2014 According to ... "Biophotonics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 25.16 billion in 2013, which is ... at a CAGR of 10.4% from 2014 to 2020. ... http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand for accurate early ...
(Date:8/1/2014)... Toronto, Canada (PRWEB) August 01, 2014 ... what should it cost? This webinar will discuss how ... construction. , Join speakers Bob Allen, Senior Director ... Director of Process Engineering at Fluor Industrial Services, and ... supporting Manufacturing Asset Planning at Amgen, as they provide ...
(Date:8/1/2014)... RUTHERFORD, N.J., Aug. 1, 2014 Cambrex Corporation (NYSE: ... ended June 30, 2014. Highlights ... $61.6 million in the same period last year. , ... $11.4 million in the same period last year (see table ... 2014 sales guidance increased, excluding the impact of foreign currency, ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16
... Inc., a consulting firm,providing outcomes research and health ... announces the addition of,Anthony J. Vita, MD, MPH ... clinical,professionals. The specialized background of these two practitioners ... directly to those clients,seeking to enhance the clinical ...
... Palatin Technologies,Inc. (Amex: PTN ) will announce its ... 2007 before the open of the U.S. financial,markets. ... audio webcast,hosted by Palatin,s executive management team on November ... operations in greater detail and provide,an update on corporate ...
... SOUTH SAN FRANCISCO, Calif., Nov. 5 Exelixis,Inc. ... for the third quarter,ended September 30, 2007. ... were $26.8 million,compared to $23.5 million for the ... 2006 to 2007 was primarily due to revenue ...
Cached Biology Technology:EPI-Q, Inc. Expands Capabilities with Addition of Anthony Vita, MD, MPH and Peter Herout, PharmD 2Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 3Exelixis Announces Third Quarter 2007 Financial Results and Business Update 4Exelixis Announces Third Quarter 2007 Financial Results and Business Update 5Exelixis Announces Third Quarter 2007 Financial Results and Business Update 6Exelixis Announces Third Quarter 2007 Financial Results and Business Update 7Exelixis Announces Third Quarter 2007 Financial Results and Business Update 8
(Date:8/1/2014)... NY, August 1, 2014Lesbian, gay, bisexual, and transgender individuals ... same problems as some of their heterosexual and cisgendered ... often face additional physiological and legal challenges to ... advances in assisted reproduction options is presented in the ... Possibilities ," published in LGBT Health ...
(Date:8/1/2014)... eye diseases is tricky enough. Knowing what causes them ... Now, University of Iowa researchers have created the most ... human eye long associated with blinding diseases, such as ... of proteins in the choroid, which supplies blood and ... By seeing differences in the abundance of proteins in ...
(Date:8/1/2014)... Sieve elements are a key component of phloem, the ... wide range of signalling molecules. Elongated cylindrical cells are ... arranged end-to-end to form sieve tubes which in turn ... "Sieve elements are very special cells which play ... very little has been known about their differentiation," says ...
Breaking Biology News(10 mins):Advances in assisted reproduction create more options & new legal issues for LGBT couples 2A map for eye disease 2Developmental regulation of important plant phloem components discovered 2
... years, researchers have worked to develop a number of ... vaccines are not intended to prevent cancer; rather, they ... Unlike traditional chemotherapy, vaccines have relatively low toxicity and, ... these vaccines have rarely been designed to directly stimulate ...
... physics to show how our circadian clocks manage to ... , In an article appearing March 13 in the ... Federale de Lausanne demonstrate that the stability of cellular ... studies in families affected by advanced sleep phase syndrome. ...
... role in the development of the placenta, the organ that ... fetus during pregnancy, and perhaps in miscarriages. , Those ... gene in mice. In humans, this gene, when mutated, raises ... retinoblastoma. Two decades ago, it was identified as the first ...
Cached Biology News:Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 2Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 3Keeping the body in sync -- The stability of cellular clocks 2Tumor-suppressor gene is critical for placenta development 2Tumor-suppressor gene is critical for placenta development 3
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... Synthetic peptide derived from an internal region ... target of rapamycin FRAP RAFT1 RAPT1). ... On Western blots it identifies the ... Human (positive control: HEK293 cell lysates). Based ...
...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Biology Products: